Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Article

Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs

Barbara Yawn, MD, MSc, FAAFP and Victor Kim, MD
Cleveland Clinic Journal of Medicine February 2018, 85 (2 suppl 1) S28-S37; DOI: https://doi.org/10.3949/ccjm.85.s1.05
Barbara Yawn
Department of Family and Community Health, University of Minnesota, Blaine, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Kim
Department of Thoracic Medicine and Surgery, Temple University School of Medicine, Philadelphia, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    2017 updates to the GOLD ABCD assessment tool3

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Current pharmacologic treatment algorithms by GOLD grades A–D3

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    COPD Foundation Pocket Consultant Guide

Tables

  • Figures
    • View popup
    TABLE 1

    COPD Foundation treatment guidelines48

    Short-acting bronchodilatorLAMA or LABA or LAMA plus LABAICS/LABARoflumilastOxygenExercise/ pulmonary rehabilitationLung volume reduction surgeryAzithromycina
    Spirometry gradeb
    SG1 MildFirst line as neededPossibly second line
    SG2/3 Moderate/ SevereFirst line as neededFirst lineSecond lineSecond linec
    Regular symptomsFirst line as neededFirst lineSecond lineFirst line
    Exacerbation risk highFirst linedFirst linedSecond linecSecond line
    Oxygenation
    Severe hypoxemiaFirst line
    Episodic hypoxemiaPossibly second line
    EmphysemaSecond line in selected cases
    Chronic bronchitisSecond linec
    ComorbiditiesEvaluate and treat identified comorbid conditions as part of first-line therapy
    • Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic receptor antagonist; SG, spirometric grade.

    • ↵a Off-label use.

    • ↵b "SG1 Mild" obstruction: post bronchodilator FEV1/FVC ratio <0.7, FEV1 ≥60% predicted; "SG2 Moderate" obstruction: post bronchodilator FEV1/FVC ratio <0.7, 30%≤ FEV1 ≤60% predicted; "SG3 Severe" obstruction: post bronchodilator FEV1/FVC ratio <0.7, FEV1 <30% predicted.

    • ↵c Indicated if chronic bronchitis, high exacerbation risk, and spirometry grades 2/3 are all present.

    • ↵d LAMA, ICS/LABA, LAMA plus LABA, or LAMA plus ICS/LABA are all potential options depending on frequency of exacerbations and severity of COPD.

    • Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation. Rennard S, Thomashow B, Crapo J, et al. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2013;10(3):378–389, reprinted by permission of the publisher Taylor & Francis Ltd, http://www.tandfonline.com.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 85 (2 suppl 1)
Cleveland Clinic Journal of Medicine
Vol. 85, Issue 2 suppl 1
1 Feb 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs
Barbara Yawn, Victor Kim
Cleveland Clinic Journal of Medicine Feb 2018, 85 (2 suppl 1) S28-S37; DOI: 10.3949/ccjm.85.s1.05

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treatment Options for Stable Chronic Obstructive Pulmonary Disease: Current Recommendations and Unmet Needs
Barbara Yawn, Victor Kim
Cleveland Clinic Journal of Medicine Feb 2018, 85 (2 suppl 1) S28-S37; DOI: 10.3949/ccjm.85.s1.05
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • Introduction
    • Current COPD management guidelines
    • GOLD 2017 strategy: key updates
    • Nonpharmacologic treatment approaches
    • Pharmacologic treatment recommendations
    • Surgical and bronchoscopic interventions
    • COPD Foundation guidelines
    • Importance of managing COPD comorbidities
    • Patient monitoring
    • Unmet needs
    • Conclusions
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • New treatments for peripheral artery disease
  • Functional tricuspid regurgitation: Feasibility of transcatheter interventions
  • A practical approach to the cholesterol guidelines and ASCVD prevention
Show more Article

Similar Articles

Subjects

  • Pulmonology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire